Sign in or Register   Sign in or Register
  |  

Mouse Anti-CDKN2A Recombinant Antibody (DCS-50) (CBMAB-P0205-YC)

Provided herein is a Mouse monoclonal antibody against Human Cyclin Dependent Kinase Inhibitor 2A. The antibody can be used for immunoassay techniques, such as FC, IF, IP, IHC, WB.
See all CDKN2A antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
DCS-50
Antibody Isotype
IgG1
Application
FC, IF, IP, IHC, WB

Basic Information

Specificity
Human
Antibody Isotype
IgG1
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid in 0.09% sodium azide
Storage
Store at 4°C short term (1-2 weeks). Aliquot and store at-20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
Cyclin Dependent Kinase Inhibitor 2A
Introduction
CDKN2A generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene.
Entrez Gene ID
1029
UniProt ID
P42771
Alternative Names
ARF; CDK4I; CDKN2; CMM2; INK4; INK4A; MLM; MTS-1; MTS1; P14; P14ARF; P16; P16-INK4A; P16INK4; P16INK4A; P19; P19ARF; TP16
Function
Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein.
Biological Process
Cell cycle arrest Source: BHF-UCL
Cellular senescence Source: BHF-UCL
G1/S transition of mitotic cell cycle Source: BHF-UCL
Negative regulation of cell growth Source: BHF-UCL
Negative regulation of cell-matrix adhesion Source: BHF-UCL
Negative regulation of cell population proliferation Source: BHF-UCL
Negative regulation of cyclin-dependent protein serine/threonine kinase activity Source: BHF-UCL
Negative regulation of G1/S transition of mitotic cell cycle Source: Reactome
Negative regulation of NF-kappaB transcription factor activity Source: BHF-UCL
Negative regulation of phosphorylation Source: BHF-UCL
Negative regulation of transcription, DNA-templated Source: UniProtKB
Positive regulation of cellular senescence Source: UniProtKB
Positive regulation of macrophage apoptotic process Source: BHF-UCL
Positive regulation of smooth muscle cell apoptotic process Source: BHF-UCL
Ras protein signal transduction Source: BHF-UCL
Regulation of transcription initiation from RNA polymerase II promoter Source: Reactome
Replicative senescence Source: BHF-UCL
Senescence-associated heterochromatin focus assembly Source: UniProtKB
Cellular Location
Nucleus; Cytoplasm
Involvement in disease
The association between cutaneous and uveal melanomas in some families suggests that mutations in CDKN2A may account for a proportion of uveal melanomas. However, CDKN2A mutations are rarely found in uveal melanoma patients.
Melanoma, cutaneous malignant 2 (CMM2): A malignant neoplasm of melanocytes, arising de novo or from a pre-existing benign nevus, which occurs most often in the skin but also may involve other sites.
Familial atypical multiple mole melanoma-pancreatic carcinoma syndrome (FAMMMPC): An inherited cancer predisposition syndrome characterized by an increased risk of developing malignant melanoma and/or pancreatic cancer. Mutation carriers within families may develop either or both types of cancer.
Melanoma-astrocytoma syndrome (MASTS): Characterized by a dual predisposition to melanoma and neural system tumors, commonly astrocytoma.
PTM
Phosphorylation seems to increase interaction with CDK4.

Xu, J., Li, N., Deng, W., & Luo, S. (2021). Discovering the mechanism and involvement of the methylation of cyclin-dependent kinase inhibitor 2A (CDKN2A) gene and its special locus region in gastric cancer. Bioengineered, 12(1), 1286-1298.

Salmani, T., Ghaderian, S. M. H., Hajiesmaeili, M., Mirghaed, O. R., Rakhshan, A., Nasiri, M. J., & Mohammadi, M. (2020). Cyclin dependent kinase inhibitor 2A and miR-671-5p expression profile in Iranian glioblastoma multiforme. Gene Reports, 19, 100620.

Althakfi, W., Gazzo, S., Blanchet, M., Isaac, S., Piaton, E., Villeneuve, L., ... & Brevet, M. (2020). The value of BRCA‐1‐associated protein 1 expression and cyclin‐dependent kinase inhibitor 2A deletion to distinguish peritoneal malignant mesothelioma from peritoneal location of carcinoma in effusion cytology specimens. Cytopathology, 31(1), 5-11.

Seifi, S., Pouya, F., Rahmani, M., Mehramiz, M., Rastgar‐Moghadam, A., Gharib, M., ... & Avan, A. (2020). Association of cyclin‐dependent kinase inhibitor 2A/B with increased risk of developing breast cancer. Journal of cellular physiology, 235(6), 5141-5145.

Zhang, H. H., Mao, J. S., & Hu, W. F. (2019). Functional genetic single-nucleotide polymorphisms (SNPs) in cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) locus are associated with risk and prognosis of osteosarcoma in chinese populations. Medical science monitor: international medical journal of experimental and clinical research, 25, 1307.

Zhang, W., Kuang, P., & Liu, T. (2019). Prognostic significance of CDKN2A/B deletions in acute lymphoblastic leukaemia: a meta-analysis. Annals of medicine, 51(1), 28-40.

Agarwal, M., Bakhshi, S., Dwivedi, S. N., Kabra, M., Shukla, R., & Seth, R. (2018). Cyclin dependent kinase inhibitor 2A/B gene deletions are markers of poor prognosis in Indian children with acute lymphoblastic leukemia. Pediatric blood & cancer, 65(6), e27001.

O'Hara, S. P., Splinter, P. L., Trussoni, C. E., Pisarello, M. J. L., Loarca, L., Splinter, N. S., ... & LaRusso, N. F. (2017). ETS proto-oncogene 1 transcriptionally up-regulates the cholangiocyte senescence-associated protein cyclin-dependent kinase inhibitor 2A. Journal of Biological Chemistry, 292(12), 4833-4846.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-CDKN2A Recombinant Antibody (DCS-50)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare